CorMatrix is the world leader in cardiovascular regeneration, addressing the largest challenges in cardiovascular disease, including valvular heart disease and myocardial infarction. It is developing the CorTricuspid ECM® Valve for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The company is also expanding its epicardial repair program with its FDA cleared CorPatch® epicardial patch. CorPatch® is a second-generation extracellular matrix device engineered for epicardial placement for support and repair of weakened areas of the heart after to myocardial infarction.